Massive late postoperative bleeding after abdominal surgery in a haematologic patient with postoperative CoV-2 infection

Roberta Tutino,1,2 Luca Bonariol,1 Ezio Caratozzolo,1 Marco Massani1

SUMMARY
The role of viral infection in extrapulmonary postoperative complications in CoV-2 patients is still debated. Perioperative bleeding is rare compared with thrombotic events, but can be related to a haemorrhagic CoV-2-associated disseminated intravascular coagulopathy-like syndrome.

BACKGROUND
Severe acute respiratory syndrome CoV-2 pandemic has rapidly spread since November 2019 from the Chinese province of Wuhan to almost every part of the globe bringing about serious problems in the healthcare management of the population. In this troublesome scenario, several efforts to ensure proper standardised cures to surgical patients have been made.

The rate of inhospital CoV-2 infections reached 53.6% in high-risk countries and 84.4% in centres with >100 CoV-2 caseload.1

In large series, mortality rate after elective surgery in patients suffering perioperative infection reaches18.5%–25.6%.2,3

A postoperative infection was present in the 89.3% of dead patients after elective surgery, with a reoperation rate of 13.7% in infected patients.2

The role viral infection plays in extrapulmonary postoperative complications is still being debated.

We highlight the possible role of CoV-2-associated disseminated intravascular coagulopathy (DIC)-like syndrome as a cause of late postoperative bleeding occurrence after a planned splenectomy.

CASE PRESENTATION
We report the case of a 73-year-old man presenting a massive splenomegaly due to polycythaemia vera complicated by myelofibrosis.

Otherwise, he was a healthy patient suffering only from mild valvular heart disease.

He was scheduled for a splenectomy and admitted with a negative real-time PCR test for CoV-2 for the planned surgical intervention. The early postoperative course was uneventful apart from a splenectomy-related decrease in platelet count, but he became CoV-2 positive after exposure to an infected patient in the same hospital room.

The patient exhibited clinical features consistent with non-severe CoV-2 disease according to the WHO severity classification.4 He was transferred to the surgical CoV-2 unit under the care of multidisciplinary team, including surgeons and infectious disease consulting service.

The patient developed sudden worsening of general condition from non-severe-to-severe CoV-2 disease4 characterised by the appearance of dyspnoea and an elevation in D-dimer up to 30 946 ng/mL. He underwent a chest CT scan that showed multiple bilobar ground-glass opacities suggesting interstitial pneumonia and a massive left pleural effusion with no signs of pulmonary embolism.

A left chest tube was then inserted to drain the pleural effusion, obtaining an improvement of dyspnoea.

Six days after the diagnosis of CoV-2 infection and on postoperative day (POD) 13, the patient presented severe hypotension with a massive drop in haemoglobin levels until 55 gr/L and only a mild prolongation of prothrombin time (PT) values of 1.21 of international normalised ratio. Laboratory data are presented in table 1.

An abdomen CT scan was performed that showed the presence of a thrombus in the remnant of the splenic vein that reached the splenomesenteric confluence and a large blood collection (5.7×3.8 inch) in the left hypochondrium without signs of active bleeding.

The patient was supported with three units of packed red blood cells and a unit of platelets. After that, he underwent an urgent surgical exploration that highlighted the presence of diffuse peritoneal bleeding spots. Abdominal lavage and haemostatic patches positioning were performed. No parameters of multiple organ failure were present at the time of re-surgery for bleeding as shown in table 1.

OUTCOME AND FOLLOW-UP
After surgical revision, he was admitted to the intensive care unit (ICU) where he was extubated and re-posted to the surgical CoV-2 unit. Unfortunately, he developed fever and hypoxaemia, initially treated with high-flow oxygen support. However, the patient finally required mechanical ventilation. Initial sequential organ failure assessment score5 was 5 with an ICU mortality risk of 20.2%.

Blood, urine and pleural liquid cultures for microbiological isolation and samples for cytomegalovirus DNA were performed. Cytomegalovirus DNA resulted negative. Pleural liquid sample showed the presence of Staphylococcus epidermidis and Bacillus licheniformis. Blood cultures were positive for S. hominis.

1 Chirurgia 1, Azienda ULSS 2 Marca Trevigiana, Ospedale Regionale Treviso, Treviso, Italy
2 Dipartimento di discipline chirurgiche, oncologiche e stomatologiche, Università degli Studi di Palermo, Palermo, Italy

Correspondence to
Dr Roberta Tutino
la.tutino@gmail.com

Accepted 8 August 2021
The patient’s general conditions did not improve and he failed on POD 22 in the ICU.

**DISCUSSION**

The underlying pathophysiological mechanisms of the increased mortality rate of CoV-2 positive patients undergoing surgery is still unknown.

Mechanical ventilation, anaesthesia or tissue damage caused by the surgery may individually induce proinflammatory cytokines and immunosuppressive response, leading to life-threatening complication of CoV-2 infection.

Extrapulmonary manifestations of CoV-2 infection were observed in one-quarter to one-third of severe and critically ill hospitalised patients.²

Among them, the ones related to coagulation disorders are caused by different mechanisms of virulence of CoV-2, and in severely infected patients cause a diffuse activation of coagulation with thrombotic and also haemorrhagic events.

Development of DIC results when monocytes and endothelial cells are activated to the point of cytokine release with expression of tissue factor and secretion of von Willebrand factor, and circulation of free thrombin, uncontrolled by natural anticoagulants, can activate platelets and stimulate fibrinolysis.⁶

The International Society of Thrombosis and Haemostasis (ISTH) overt DIC diagnostic criteria consist of four laboratory findings: decreased platelet count, elevated fibrinogen and D dimer levels, and by a mild prolongation of PT/partial thromboplastin time (PTT). Also, thrombocytopenia is mild (platelet count ~100×10⁹/L), and lab results supporting microangiopathy are infrequent.⁹

The complex and still poorly understood relationship between CoV-2 and thrombogenesis seems probably being caused by a cytokine storm arising from the interaction of the virus with ACE2 receptors and the recruitment of innate immunosuppressive cells with prothrombotic features (‘viral sepsis’ like syndrome) that promote microthromboembolic and macrothromboembolic events (stroke, infarction, myocarditis and pericarditis).⁹

The ISTH overt DIC diagnostic criteria and CoV-2 DIC-like syndrome parameters are shown in table 2.

Our patient showed a haemorrhagic complication during the evolution of CoV-2 infection from non-severe to severe. He had no overt criteria for classic DIC since he showed a reduction in platelets count, that was also due to the baseline haematological disease, a D-dimer elevation, normal PT values and an elevation in fibrinogen levels with a DIC score of 4 (negative or non-over DIC) in the context of a haemorrhagic complication with multiple peritoneal petechias and bleeding spots. These data suggest the diagnosis of a CoV-2 DIC-like syndrome.

Isolated cases of spontaneous bleeding in severe or critical CoV-2 patients have been reported in the literature.

Worrall et al underlines among 35 CoV-2 patients who required critical care in their centre, major bleeding occurred in three patients (8.6%), two of whom being post abdominal surgery.¹⁰

Karki et al described a case of spontaneous haemoperitoneum from splenic infarction in a CoV-2 patient, that required surveillance in the ICU department and blood transfusion with successful non-operative management on day 7.¹¹

Conti et al reported two CoV-2 cases of haemorrhagic shock due to spontaneous ilioiliopsoas bleeding successfully treated with

---

**Table 1** Laboratory parameters of the patient

|                      | Preoperative | Day 1 | Day 5 | Day 10 | Day 13 (Re-surgery) | Day 14 | Day 20 |
|----------------------|-------------|-------|-------|--------|--------------------|--------|-------|
| Real time PCR CoV-2  | Negative    | Positive |       |        |                    |        |       |
| Platelet (10⁹/L)     | 123         | 56    | 55    | 53     | 46                 | 88     | 53    |
| White blood cells (10⁹/L) | 45.28     | 34.04 | 22.00 | 34.06  | 26.59              | 21.08  | 25.07 |
| Haemoglobin (g/L)    | 92          | 10.5  | 10.7  | 9.7    | 5.5                | 10.6   | 13.2  |
| International normalised ratio | 2.3      | 1.15  | 1.25  | 1.21   | 1.17               | 1.28   |       |
| Partial thromboplastin time (s) | 59.4 (ratio 1.93) | 26.7 (0.87) | 27.4 (0.84) | 31.4 (0.97) | 29.7 (0.91) | 29.7 (0.91) |       |
| D-dimer (ng/mL fibrinogen equivalent units) | 30946 |       |       |        |                    |        |       |
| Fibrinogen (mg/dL)   |             |       |       | 302    | 393                |        |       |
| C reactive protein (mg/dL) | 0.62   |       |       | 18.98  | 15.47              | 7.96   |       |
| Procalcitonin (ng/mL) |             |       |       | 8.66   | 0.26               |        |       |
| Aspartate transaminase (U/L) | 52      |       | 25    | 37     | 46                 |        |       |
| Alanine aminotransferase (U/L) | 15    |       | 8     | 14     | 26                 |        |       |
| Alkaline phosphatase (U/L) | 134      | 114   | 216   | 111    | 305                |        |       |
| Total bilirubin (mg/dL) | 0.7      | 0.6   | 0.8   | 0.5    | 1.0                |        |       |
| Direct bilirubin (mg/dL) | 0.4      |       |       | 0.3    | 0.7                |        |       |
| Creatinine (mg/dL)   | 0.75        | 0.65  | 0.54  | 0.48   | 0.46               | 0.42   |       |

---

**Table 2** ISTH DIC criteria and CoV-2 DIC-like syndrome criteria

| Platelet count | < | <<< |
| Fibrin-related biomarkers (D-dimer) | >>> | >>> |
| Prothrombin time | > | >>> |
| Fibrinogen level | <<< | <<< |

DIC, disseminated intravascular coagulopathy; ISTH, International Society of Thrombosis and Haemostasis.
interventional radiology embolisation of the inferior epigastric artery in CoV-2 patients. The authors couldn't relate these bleedings to coagulation disorders since the coagulation factors PT, PTT and platelets were normal in both cases.12

Our patient showed persistent postoperative low platelet count, which in haematological patient is not commonly responsible for postoperative bleeding based on our previous experience.

Shaukat et al reported a case of haemoperitoneum due to a spontaneous splenic rupture in a normal size spleen. The patient was initially transfused with packed red cells, fresh frozen plasma and treated with intravenous tranexamic acid. Then the patient underwent splenic artery embolisation procedure with improvement of haemodynamic conditions. Subsequently, he needed a tracheostomy and after being healed from urosepsis, he was discharged on day 24.13

Bargellini et al reported four consecutive cases of spontaneous bleeding who underwent endovascular embolisation.14

Jonker et al evaluating 30-day overall mortality in patients with a perioperative CoV-2 positive status found an OR of 3.4 (95% CI 1.5 to 8.5) compared with negative control patients. Pulmonary complications occurred in 25 (20%) CoV-2 positive patients versus 6 (3%) in matched CoV-2 negative patients (p<0.001). The number of patients with thromboembolic events was greater in the CoV-2 positive group (8 (7%) vs 1 (0.5%); p=0.004). However, the authors showed no difference in haemorrhagic or infectious complications between matched cohorts.15

Al-Samkari and colleagues evaluated the incidence of bleeding and thrombotic event in a series of 400 CoV-2 positive patients admitted to the hospital. The overall thrombotic complication rate was 9.5% (95% CI, 6.8 to 12.8; 45 events in 38 patients) and four patients with thrombotic complications also developed bleeding complications. The overall bleeding rate was 4.8% with 21 bleeding events in 19 patients (95% CI, 2.9 to 7.3). This included a rate of 3.1% (95% CI, 1.4 to 6.1), or 3.49/100 non-critically ill patient weeks and 7.6% (95% CI, 3.9 to 13.3), or 5.63/100 critically ill patient weeks.16

The difference between classic DIC and CoV-2 DIC-like syndrome criteria underline how thrombotic and bleeding manifestations of CoV-2 infection are probably due to a distinct pathophysiological viral coagulopathy than a simply coagulation system activation in the setting of a severe inflammation.

Of course, in CoV-2 patients thrombotic events overcome the haemorrhagic ones and our hypothesis can be speculative, being limited to a single case.

However, it would be interesting to evaluate CoV-2 DIC-like criteria in other patients suffering haemorrhagic manifestations and a CoV-2 infection.

Contributors RT and MM gave substantial contributions to the conception and outline of this paper; RC and EC gave substantial contributions to the acquisition, analysis and interpretation of data for the work; RT drafted the work; LB and MM revised it critically for important intellectual content; all the authors gave their final approval of the version to be published and ensure that questions related to the accuracy or integrity of any part of the work have been appropriately investigated and resolved.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Patient consent for publication Next of kin consent obtained.

Provenance and peer review Not commissioned; externally peer-reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Roberta Tutino http://orcid.org/0000-0002-0891-4689

REFERENCES
1 Bellot U, Konishi T, Pelling G, et al. Screening policies, preventive measures and in-hospital prevention of COVID-19 in global surgical practices. J Glob Health 2020;10:020507.
2 COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 2020;396:27–38.
3 Fernández-Martínez M. Overall management of emergency general surgery patients during the surge of the COVID-19 pandemic: an analysis of procedures and outcomes from a teaching hospital at the worst hit area in Spain. Eur J Trauma Emerg Surg 2021;1–10.
4 WHO clinical management of Covid-19—Interim guidance. Available: https://www.who.int/publications/i/item/clinical-management-of-covid-19 [Accessed 29 Jun 2020].
5 Vincent JL, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. on behalf of the Working group on sepsis-related problems of the European Society of intensive care medicine. Intensive Care Med 1996;22:707–10.
6 Fang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.
7 Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 2019;17:1989–94.
8 American Society of Hematology (ASH): COVID-19. What is COVID-19-associated coagulopathy? is it any different from disseminated intravascular coagulopathy (DIC)? Available: https://www.hematology.org/covid-19/covid-19-and-coagulopathy
9 Melenotte C, Silvin A, Goubet A-G, et al. Immune responses during COVID-19 infection. Oncoimmunology 2020;9:1807836.
10 Worrall AP, Kelly C, O’Neill A, et al. Transfusion requirements in patients with COVID-19. Eur J Haematol 2021;106:132–4.
11 Karki S, Rawal SB, Malla S, et al. A case report on spontaneous hemoperitoneum in COVID-19 patient. Int J Surg Case Rep 2020;75:211–3.
12 Conti CB, Henchi S, Coppeta G, et al. Bleeding in COVID-19 severe pneumonia: the other side of abnormal coagulation pattern? Eur J Intern Med 2020;77:147–9.
13 Shaukat I, Khan R, Diwakar L, et al. Atypical splenic rupture due to COVID-19 infection. Clin Infect Pract 2021;10:100042.
14 Bargellini I, Cervelli R, Lunardi A, et al. Spontaneous bleedings in COVID-19 patients: an emerging complication. Cardiovasc Intervent Radiol 2020;43:1095–106.
15 Jonker PKC, van der Plas WY, Steinkamp PJ, et al. Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: a Dutch, multicenter, matched-cohort clinical study. Surgery 2021;169:264–74.
16 Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489–500.
